Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ixabepilone - R Pharm

Drug Profile

Ixabepilone - R Pharm

Alternative Names: Azaepothilone B; BMS-247550; Epothilone B analogue; Ixempra; NSC 710428; Patupilone analogue

Latest Information Update: 10 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GBF
  • Developer Bristol-Myers Squibb; R-Pharm; Yale University
  • Class Antineoplastics; Epothilones; Macrolides; Small molecules
  • Mechanism of Action Cell cycle inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase II Ovarian cancer
  • No development reported Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer
  • Discontinued Cancer; Endometrial cancer; Prostate cancer

Most Recent Events

  • 04 Apr 2019 Oncology Venture A/S acquires an option to in-license the European rights from R-Pharm to ixabepilone
  • 04 Apr 2019 Launched for Breast cancer (Second-line therapy or greater) in Liechtenstein (IV) Prior to April 2019
  • 04 Apr 2019 Oncology Venture intends to seek EMA approval to market ixabepilone in Europe for Breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top